Samsung Seoul Hospital Surpasses 100 Cases of 'Dream Cancer Drug' CAR-T Therapy

Samsung Medical Center announced on the 6th that it has surpassed 100 cases of CAR-T cell therapy.

Samsung Seoul Hospital Celebrates 100 Cases of CART-Cell Therapy.
[Photo by Samsung Seoul Hospital]

Since starting CAR-T cell therapy for refractory B-cell lymphoma patients in April 2021, the first in Korea, Samsung Medical Center has recorded 109 cases as of today. It was the first in the country to establish a 'CAR T-Cell Therapy Center' and is operating a multidisciplinary-based treatment system.

The main departments, Hematology-Oncology and Pediatrics, along with tumor specialist nurses, are treating patients. A multidisciplinary treatment and systematic management system involving medical staff from departments such as Laboratory Medicine, Neurology, Infectious Diseases, and Intensive Care Medicine has been established to improve treatment outcomes.

Samsung Medical Center is also leading research on CAR-T cell therapy. It has performed the first domestic CAR-T cell therapy targeting 'CD19 (B-cell antigen)' for adult acute B-lymphoblastic leukemia patients and 'BCMA (B-cell maturation antigen)' targeting CAR-T cell therapy for refractory multiple myeloma patients.

Center Director Kim Won-seok said, "Beyond being the first in Korea to start CAR-T cell therapy, we will make this center the best at CAR-T cell therapy," adding, "We will strive to provide more diverse treatment options so that more hematologic cancer patients can receive better treatment."

This content was produced with the assistance of AI translation services.